(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 May 2013 (02.05.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/063346 A1

(51) International Patent Classification:
A01K 67/027 (2006.01)

(21) International Application Number:
PCT/US2012/062042

(22) International Filing Date:
26 October 2012 (26.10.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/552,587	28 October 2011 (28.10.2011)	US
61/552,582	28 October 2011 (28.10.2011)	US
61/700,908	14 September 2012 (14.09.2012)	US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(72) Inventors: **MACDONALD, Lynn**; 16 Gedney Way, White Plains, NY 10605 (US). **MURPHY, Andrew, J.**; 10 Newton Court, Croton-on-Hudson, NY 10520 (US). **GURER, Cagan**; 8 Pamela Lane, Valhalla, NY 10594 (US). **MCWHIRTER, John**; 2035 Crescent Drive, Tarrytown, NY 10591 (US). **VORONINA, Vera**; 33 Gramercy Pl., Thornwood, NY 10594 (US). **HARRIS, Faith**; 321 Florence St., Mamaroneck, NY 10543 (US). **STEVENS, Sean**; 355 Berry Street Apt. 413, San Francisco, CA 94158 (US).

(74) Agent: **ZIPPIN, Margarita**; Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2013/063346 A1

(54) Title: GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE

(57) Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized beta2 microglobulin polypeptide, as well as non-human embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.